<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01009242</url>
  </required_header>
  <id_info>
    <org_study_id>RA0010</org_study_id>
    <secondary_id>2009-010813-57</secondary_id>
    <nct_id>NCT01009242</nct_id>
  </id_info>
  <brief_title>To Evaluate the Blood Levels and Safety of IV and Subcutaneous CDP6038 in Subjects With Rheumatoid Arthritis Using Methotrexate</brief_title>
  <official_title>A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Single Dose Evaluation of the Pharmacokinetics, Pharmacodynamics and Safety of IV and Subcutaneous CDP6038 in Subjects With Rheumatoid Arthritis on a Stable Dose of Methotrexate</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>UCB Pharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>UCB Pharma</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objectives are to determine the relationship between blood levels of CDP6038 and
      suppression of C-reactive Protein (CRP) following single doses given as intravenous (IV)
      infusion or subcutaneous (SC) injection to Rheumatoid Arthritis (RA) patients. The safety of
      CDP6038 will also be evaluated.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The secondary objectives of the study include determination of the absolute bioavailability
      of CDP6038 given via sc administration compared with iv infusion; assessment of the
      immunogenicity potential of single dose CDP6038 and assessment, on an exploratory basis, of
      other relevant systemic biomarkers and changes in clinical response.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2009</start_date>
  <completion_date type="Actual">September 2010</completion_date>
  <primary_completion_date type="Actual">September 2010</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>PK/PD relationship between systemic CDP6038 exposure and CRP suppression.</measure>
    <time_frame>For 12 weeks following single dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Evaluate the safety and tolerability of single doses of CDP6038 For 12 weeks following single dose</measure>
    <time_frame>For 12 weeks following single dose</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Absolute bioavailability of CDP6038 given by sc injection in comparison with iv infusion</measure>
    <time_frame>For 12 weeks following single dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assess the immunogenicity of single dose CDP6038</measure>
    <time_frame>Multiple sampling from 0 to 12 weeks following single dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assess, on an exploratory basis, changes in clinical response and other systemic biomarkers associated with RA</measure>
    <time_frame>For 12 weeks following single dose</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Arthritis</condition>
  <condition>Rheumatoid Arthritis</condition>
  <arm_group>
    <arm_group_label>0.1mg/kg and 1mg/kg CDP6038 IV and Placebo IV</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cohort 1, Group 1 will compare 0.1mg/kg, 1mg/kg CDP6038 and placebo IV.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>1 mg/kg CDP6038 SC and Placebo SC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cohort 1, Group 2 will compare 1mg/kg CDP6038 and placebo sc.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Optimized CDP6038 SC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cohort 2, Group 3 will compare optimized sc doses of CDP6038 based on outcome of Cohort 1 with placebo.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>CDP6038</intervention_name>
    <description>Single dose:
1 mg/kg CDP6038 IV</description>
    <arm_group_label>0.1mg/kg and 1mg/kg CDP6038 IV and Placebo IV</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>CDP6038</intervention_name>
    <description>Single dose:
0.1mg/kg CDP6038 IV</description>
    <arm_group_label>0.1mg/kg and 1mg/kg CDP6038 IV and Placebo IV</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>CDP6038</intervention_name>
    <description>Single dose:
1.0mg/kg CDP6038 SC</description>
    <arm_group_label>1 mg/kg CDP6038 SC and Placebo SC</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo IV</intervention_name>
    <description>Single dose:
Placebo IV</description>
    <arm_group_label>0.1mg/kg and 1mg/kg CDP6038 IV and Placebo IV</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo SC</intervention_name>
    <description>Single dose:
Placebo SC</description>
    <arm_group_label>1 mg/kg CDP6038 SC and Placebo SC</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CDP 6038 SC</intervention_name>
    <description>Optimized CDP6038 SC doses based on outcome of Cohort 1 with placebo</description>
    <arm_group_label>Optimized CDP6038 SC</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  RA &gt; 6 months duration on stable Methotrexate

          -  ≤9 swollen and ≤9 tender joints (28 joint count)

          -  Minimum Screening CRP of 0.5mg/L

        Exclusion Criteria:

          -  Participation in previous studies with defined agents and durations

          -  Previous treatment with defined agents and durations

          -  Presence of, or history of defined medical conditions including those particularly
             associated with deficiency in immune response

          -  Pregnancy

          -  Positive tests/signs of possible latent/active tuberculosis

          -  Positive HIV

          -  Drug addiction or alcohol abuse
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>UCB Clinical Trial Call Center</last_name>
    <role>Study Director</role>
    <affiliation>+1 877 822 9493 (UCB)</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Duncansville</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cologne</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Erlangen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 4, 2009</study_first_submitted>
  <study_first_submitted_qc>November 4, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 6, 2009</study_first_posted>
  <disposition_first_submitted>October 3, 2011</disposition_first_submitted>
  <disposition_first_submitted_qc>October 3, 2011</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">October 5, 2011</disposition_first_posted>
  <last_update_submitted>August 26, 2014</last_update_submitted>
  <last_update_submitted_qc>August 26, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 27, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>CDP6038</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Methotrexate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

